Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRajshekhar ChakrabortyAJArnaud JaccardYKYawara Kawano

Discussion

Loading...

Member takes

Overview

Initial phase 1/2 trial shows etentamig achieves complete response in relapsed light chain amyloidosis, suggesting a promising immunotherapy option.

Key Points

  • Initial results show complete response rate of 83% with etentamig in patients with light chain amyloidosis.
  • All patients in the dose level 1 cohort maintained hematologic response with 100% achieving at least very good partial response.
  • Observational analysis of treatment-emergent adverse events including low-grade cytokine release syndrome in participants.
  • Findings indicate that etentamig is a promising bispecific antibody for treating this challenging condition.

Cite This Study

Chakraborty et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236dda8https://doi.org/10.1182/blood-2025-692
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses2025
  2. 2Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study2025 · 2 citations
  3. 3A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results2025 · 1 citations
  4. 4Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis2025
  5. 5Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma2025